SynBioBeta Speaker
Colin Harvey
Hexagon Bio
Co-founder & VP, Early Discovery
Colin Harvey, PhD is Co-Founder and VP of Early Discovery at Hexagon Bio, where he leads efforts to harness microbial genomics and synthetic biology to discover novel therapeutics from nature. His work focuses on mining fungal genomes to uncover new bioactive compounds and translate them into drug candidates.Colin completed his PhD in Chemistry at Stanford University under Chaitan Khosla, where he developed approaches for engineering natural product biosynthesis, and subsequently conducted postdoctoral research with Ronald W. Davis at the Stanford Genome Technology Center where his work helped pioneer scalable platforms for heterologous expression and discovery of cryptic natural products.Since co-founding Hexagon Bio in 2017, Colin has built and led interdisciplinary teams integrating genomics, computation, and synthetic biology to systematically unlock new chemical space from the microbial world.
SynBioBeta 2026 Tickets are Live
Confirmed Speakers
Sessions Featuring
Colin
This Year
Session lineup still growing
Featuring
Speaker Coming Soon
•
-
Human Health
From Cells to Patients: Solving the Scale Mismatch in Virtual Biology
Drug discovery often measures biology at the cell level while interventions work at the tissue, organ, or whole-patient scale. This mismatch can make accurate cell-level predictions irrelevant in the clinic. This session dives into strategies to bridge that gap: multiscale modeling that nests single-cell dynamics within organ-level simulations, spatial transcriptomics that preserve context, and surrogate models that translate cell-level outputs into clinical biomarkers. Speakers will ask: how do we ensure virtual biology reflects not just what cells do in isolation, but how biology behaves in the real complexity of patients?
Featuring
Speaker Coming Soon
